MIN 101

Drug Profile

MIN 101

Alternative Names: CYR-101; MIN-101; MT-210

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 22 Jun 2017 Minerva Neurosciences files for patent protection with USPTO for GR formulation of MIN 101 in USA
  • 22 Jun 2017 Pharmacokinetics data from a phase I trial in Schizophrenia released by Minerva Neurosciences
  • 22 Jun 2017 Minerva Neurosciences completes a phase I trial in Schizophrenia (In volunteers) in Ireland (PO, Controlled-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top